Holding in Nanoscience

IP2IPO Group PLC
07 November 2005




For immediate release                                       7 November 2005

                              IP2IPO GROUP PLC


          ACQUISITION OF TOUMAZ TECHNOLOGY LIMITED BY NANOSCIENCE INC


IP2IPO Group plc (AIM: IPO) ('IP2IPO'), the intellectual property
commercialisation company, is pleased to announce completion of the acquisition
of Toumaz Technology Limited ('Toumaz') (in which IP2IPO had a 5.3 per cent.
interest) by Nanoscience Inc (AIM: NAN) ('Nanoscience').


IP2IPO received 5,098,167 ordinary shares of 0.25p each in Nanoscience
(Nanoscience Shares), representing 2.8 per cent. of Nanoscience's current issued
share capital as consideration for its holding in Toumaz. IP2IPO has sold
5,098,167 Nanoscience shares to institutional and founder shareholders receiving
net proceeds of £762,430. Following this notification IP2IPO holds no further
Nanoscience shares.


The press release issued by Nanoscience on Wednesday 2 November follows below.





                  Immediate release: Wednesday 2 November 2005

                                                                    
                                Nanoscience Inc.


                        ('Nanoscience' or 'the Company')


                                 Result of EGM


The Board of Nanoscience is pleased to announce that at the Extraordinary
General Meeting of the Company held this morning, all of the resolutions
proposed in the Notice of EGM, details of which were set out in the circular to
shareholders dated 10 October 2005, were duly passed.


The resolutions were in relation to, inter alia, the acquisition of Toumaz
Technology Limited through the issue of 96,337,210 new Acquisition Shares at a
price of 18.4p per share and to authorise the issue of the Acquisition Shares
and the 47,333,333 new Placing Shares at a price of 15p per share pursuant to
the Placing which has raised £7.1 million before expenses. The Acquisition and
Placing are conditional on Admission.


Application has been made to the London Stock Exchange for the re-admission of
the 40,100,000 Existing Ordinary Shares, and the admission of the Acquisition
Shares and Placing Shares to trading on AIM. It is expected that Admission will
become effective and that dealings in the Existing Ordinary Shares, Acquisition
Shares and Placing Shares, representing in aggregate 183,770,543 ordinary
shares, will commence on 3 November 2005.


Completion of the Acquisition is due to take place on 3 November 2005. Professor
Christofer Toumazou, aged 44, will be appointed as an additional non-executive
director of the Company with effect from completion of the Acquisition. Other
than as set out below, there is no further information to be disclosed under
paragraph (g) of Schedule 2 of the AIM Rules.


Chris Toumazou's past and current directorships within the last five years are:



Current


Bio-Life Technology Limited


Bio-Nano Sensium Technologies Limited


Cardioassist Limited


DNA Electronics Limited


LTP Electronics Limited


Toumaz Technology Limited


Past


Lambda Technology Limited


Oxtek Limited


Unless the context otherwise requires, defined terms used in this announcement
shall have the meanings given to them in the circular to shareholders of the
Company dated 10 October 2005.



For more information please contact:


IP2IPO                                                         020 7489 5200
David Norwood, Chief Executive Officer



Buchanan Communications                                         020 7466 5000
Tim Anderson, Mark Court, Mary-Jane Johnson







Notes for editors


IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company was founded in 2001 and
listed on the AIM Market of the London Stock Exchange plc in October 2003.
IP2IPO's first partnership was with the University of Oxford. In return for an
investment of £20 million, IP2IPO has acquired 50 per cent of the University of
Oxford's equity in spin-out companies and technology licenses based on
intellectual property created at the Chemistry Department until 2015. In
November 2003, IP2IPO created a £5 million seed capital fund for investing in
spin-out companies across the University of Oxford, not just those originating
within the Chemistry Department.


In March 2002, IP2IPO entered into a second long-term partnership with the
University of Southampton. Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies. In addition, IP2IPO also received a 20 per cent stake in Southampton
Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its spin-out companies. The partnership has a term
of at least 25 years.


IP2IPO entered into its third long-term partnership in May 2003 with King's
College London. IP2IPO will work with King's College London to help identify and
progress commercialisation opportunities as well as invest £5 million in seed
capital in spin-out companies from King's College London over a five year period
in return for equity stakes in those companies. In addition, IP2IPO will receive
20 per cent of King's College London's equity in spin-out companies and
technology licenses. The partnership has a term of 25 years.


In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has
invested £1.15m in Amaethon Limited in return for a 40% equity stake in Amaethon
Limited (the remaining equity being owned by the University of York) and will
also invest in the spin-out companies based on CNAP's IP which Amaethon Limited
creates.


In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment
adviser to early stage technology funds. This combines IP2IPO's expertise in the
creation of new ventures based on world leading university IP with Top
Technology's focus on making early stage venture capital investments.


In January 2005, IP2IPO acquired Techtran, a company set up in 2002 to
commercialise university intellectual property under a long-term technology
commercialisation contract with the University of Leeds. Under the terms of the
contract Techtran receives a significant (30%) interest in spin-out companies
created and technology licences negotiated, in return for the provision of
technology transfer services to the University.


In May 2005, IP2IPO announced the launch of LifeUK, a new subsidiary company.
LifeUK, which has since been renamed Modern Biosciences, will in-license life
science intellectual property created by medical researchers at universities
with which IP2IPO already has partnerships, other universities in the UK and
similar academic and charitable research institutions. Modern Biosciences'
objective is to further develop the intellectual property which it in-licenses
with a view to creating substantial value either by subsequently licensing these
development programmes to the pharmaceutical industry or via the creation of new
ventures.


To date, 5 spin-out companies from the IP2IPO portfolio have listed on the AIM
Market of the London Stock Exchange plc: Offshore Hydrocarbon Mapping plc,
Synairgen plc, VASTox plc, Proximagen Neuroscience plc and GETECH Group plc.




                      This information is provided by RNS
            The company news service from the London Stock Exchange